Hot Stocks: Kinross Gold Corporation, Yamana Gold Inc. (USA)(NYSE:AUY), National Bank of Greece (ADR)(NYSE:NBG), MannKind Corporation(NASDAQ:MNKD)
Kinross Gold Corporation (USA)(NYSE:KGC) shares decreased 2.88% to $6.40. The company on May 7 reported net income for the first quarter of US$160.5 million or US$0.14 per share, compared to US$99.6 million or US$0.09 per share for the year-ago quarter. Adjusted net income for the first quarter was US$170.5 million or US$0.15 per share, compared to US$196.1 million or US$0.17 per share in the prior year quarter. Revenue for the first quarter rose to US$1.06 billion from US$1.01 billion a year ago. First quarter production totaled 648,897 gold equivalent ounces, compared with 588,358 ounces in the first quarter of last year.
Yamana Gold Inc. (USA)(NYSE:AUY) shares decined 1.67% to $11.76. The company, on April 30, said its first-quarter earnings fell 40% as metals prices declined, despite higher production at the Canada-based gold mining company. The company posted a profit of $102.1 million, or 14 cents a basic share, down from $170 million, or 23 cents a share, a year earlier. Adjusted per-share earnings decreased to 16 cents from 25 cents. Revenue slid 4.4% to $534.9 million. Analysts had forecast a per-share profit of 18 cents on revenue of $565 million.
National Bank of Greece (ADR)(NYSE:NBG) shares declined 0.98% to $6.06. The company, on May 24, reported a profit for the second consecutive quarter, helped by its Turkish subsidiary Finansbank, as well as lower funding costs and provisions for bad debt. The bank posted net profit of 27 million euros in the first quarter compared to a loss of 731 million in the same period last year. NBG said loan-loss provisions fell to 428 million euros from 505 million euros.
MannKind Corporation(NASDAQ:MNKD) shares decreased 1.83% to $7.49. The company on May 31 announced that all follow-up visits have been completed for the patients enrolled in Study 171, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) inhalation powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind’s next-generation inhaler. MannKind expects to release data from this study later this summer.
Tags: Kinross Gold Corporation, MannKind Corporation(NASDAQ:MNKD), National Bank of Greece (ADR)(NYSE:NBG), Yamana Gold Inc. (USA)(NYSE:AUY)